Generic name: Tretinoin 10mg
Dosage form: capsule
Medically reviewed on April 2, 2018.
The recommended dose is 45 mg/m2/day administered as two evenly divided doses until complete remission is documented. Therapy should be discontinued 30 days after achievement of complete remission or after 90 days of treatment, whichever occurs first.
If after initiation of treatment of VESANOID the presence of the t(15;17) translocation is not confirmed by cytogenetics and/or by polymerase chain reaction studies and the patient has not responded to VESANOID, alternative therapy appropriate for acute myelogenous leukemia should be considered.
VESANOID is for the induction of remission only. Optimal consolidation or maintenance regimens have not been determined. All patients should, therefore, receive a standard consolidation and/or maintenance chemotherapy regimen for APL after induction therapy with VESANOID, unless otherwise contraindicated.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Vesanoid (tretinoin)
- Vesanoid Side Effects
- During Pregnancy or Breastfeeding
- Drug Images
- Drug Interactions
- Compare Alternatives
- En Español
- 1 Review
- Drug class: miscellaneous antineoplastics